Ann: Immutep Investor Update, page-46

Two 'prudent' financial decisions:-
capital raise - July @ 0.021
Recent share consolidation 10:1 @ 0.028
History would indicate either of above would lead to SP retrace 10-20%.
Positive data TACTI-002 (and TACTI-Mel to a lesser extent) helped shore up SP for a while and now we are seeing the inevitable pull back - in the absence of any substantive news.
There are subtle hints from management ( that many long term SHs picked up on) for example huge increase in Efti manufacturing capability that suggests AIPAC is going to plan and if data results are in line with previous smaller cohorts, will be the pivotal moment in Immuteps history.
All that said - it's not easy seeing daily grind of SP moving south - especially when other small cap biotechs are going off the map recently.
For sake of transparency I've been in PRR - IMM for around 10 years. Rarely post on HC.
Marc deserves a medal (gold if AIPAC is successful) for turning around a single trick pony to potentially a 'multi stallion' billion market cap business.